{'fraction_non_alphanumeric': 0.025358324145534728, 'fraction_numerical': 0.007717750826901874, 'mean_word_length': 5.34965034965035, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In this issue

The use of cells to carry vectors to metastatic tumours has become increasingly attractive in order to protect them from neutralisation, sequestration or mis-localisation. In this study, Lang et al. used an in vivo screen to identify populations of bone marrow-derived donor cells, which accumulate within tumors. Unsorted bone marrow (BM) cells from green fluorescent protein (GFP)transgenic donor mice were adoptively transferred into C57Bl/6 mice bearing pre-established subcutaneous B16 melanoma tumors and tumors, organs and blood were subsequently analyzed for the presence of GFPexpressing cells by flow cytometry. CD45+ hematopoietic cells were readily detected in tumor, spleen, bone marrow, blood and lung. This study will direct rational selection of specific cell types, which can be tested in standardized assays of cell carrier efficiency for the treatment of metastatic tumors.